MNI BRIEF: German Economy "Treading Water", Prices Stable -Ifo

MNI BRIEF: China To Release Childcare Subsidies, Boost Income

MNI: ITALY FEB HICP 0.1% M/M, 1.7% Y/Y

MNI BRIEF: PBOC Mulls New Tools Targeting Consumption

MNI BRIEF: China House Prices Up In February

MNI BRIEF: China Data Shows Good Foundation Despite Issues

EZ/UK Bond Supply Calendar: UK, Finland Due Tuesday

EZ/UK T-Bill Calendar: 6-Month ESM-Bill Auction on Tuesday

MNI: US JAN BUSINESS INVENTORIES +0.3%; SALES -0.8%

GERMANY: Union/SPD Migration Alignment After Turmoil Threatened Debt Deal (BILD)

GERMANY: Official Interim Election Results Tilt Towards Missing BSW & FDP

© 1982-2025 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

HEALTHCARE: Fresenius Medical (FMEGR: Baa3/BBB-/BBB-): DaVita outlook

HEALTHCARE
Credit BulletsCEEMEAEurozoneGermanyBullet
  • DaVita shares fell around 7% overnight on a disappointing outlook
  • DVA reported Dialysis revenues of $12.3bn +5.9% and overall NetIncome +39% yoy.
  • The stock was well-rated and the fall more reflects lofty expectations.
  • FMEGR and DVA have a near duopoly in the US Dialysis market controlling over 2/3 of outpatient dialysis clinics.
  • c70% of FMEGR's earnings are from the US
  • The FTC opened an enquiry into DaVita/FMEGR's non-compete agreements in July. This is not their first enquiry. A new Health Secretary may be more aggressive. It's hard to see how "Trump Tariffs" per se would affect FMEGR as the company operates directly in the US.
100 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • DaVita shares fell around 7% overnight on a disappointing outlook
  • DVA reported Dialysis revenues of $12.3bn +5.9% and overall NetIncome +39% yoy.
  • The stock was well-rated and the fall more reflects lofty expectations.
  • FMEGR and DVA have a near duopoly in the US Dialysis market controlling over 2/3 of outpatient dialysis clinics.
  • c70% of FMEGR's earnings are from the US
  • The FTC opened an enquiry into DaVita/FMEGR's non-compete agreements in July. This is not their first enquiry. A new Health Secretary may be more aggressive. It's hard to see how "Trump Tariffs" per se would affect FMEGR as the company operates directly in the US.